论文部分内容阅读
本组９７例晚期癌症经用去甲－５′－脱氢长春花碱（ＮＶＢ）为主的联合化疗，缓解率为６０．８％（５９／９７），非小细胞肺癌用ＮＶＢ＋ＩＦＯ＋ＤＤＰ；转移性乳癌用ＮＶＢ＋ＩＦＯ＋ＡＤＭ；复发、难治恶性淋巴瘤用ＮＶＢ＋ＩＦＯ＋ＡＤＭ＋ＰＤＮ；晚期卵巢癌用ＮＶＢ＋ＣＴＸ＋ＤＤＰ等。ＮＶＢ对原发灶和转移灶均有效，且对转移灶的疗效较为突出。ＮＶＢ化疗可使部分晚期病例的病期降低，为手术创造有利条件。ＮＶＢ的剂量为每次２５～３０ｍｇ／ｍ￣２，疗程剂量为２００ｍｇ。毒副反应以骨髓抑制最常见，也最严重，发生率为７０．１％（６８ｌ９７），Ⅲ～Ⅳ度毒性４９．５％（４８／９７），但均为可逆的，经积极处理均可恢复；局部静脉炎、消化道反应亦较常见。骨髓抑制为ＮＶＢ的剂量限制毒性。含ＮＶＢ的联合化疗是晚期癌症综合治疗的重要措施。
In this group of 97 patients with advanced cancer were treated with norepinephrine-5′-dehydrovinblastine (NVB) combined chemotherapy, the remission rate was 60.8% (59/97), and NVB+IFO+DDP was used for non-small cell lung cancer; metastatic NVB + IFO + ADM for breast cancer; NVB + IFO + ADM + PDN for relapsed, refractory lymphoma; NVB + CTX + DDP for advanced ovarian cancer. NVB is effective for both primary and metastatic lesions, and has a prominent effect on metastases. NVB chemotherapy can reduce the stage of disease in some advanced cases and create favorable conditions for surgery. The dose of NVB is 25~30mg/m~2 each time and the treatment dose is 200mg. Myelosuppression was most common and most severe with toxicities. The incidence was 70.1% (68l97) and 49.5% (III/IV) toxicity (48/97), but both were reversible and could be treated actively. Recovery; Local phlebitis, digestive tract reactions are also more common. Myelosuppression is a dose-limiting toxicity of NVB. Combination chemotherapy with NVB is an important measure for comprehensive treatment of advanced cancer.